A proteomic signature of relapse-related death predicting clinical outcome in human non-small cell lung cancer

摘要

Lung cancer is the leading cause of cancer deaths in Japan, with loss of more than 55,000 lives annually1, also claiming a great number of lives as the number one cause of cancer death in the United States as well as in many other economically developed countries2. Surgical resection, for which about 25% of patients diagnosed with lung cancer are eligible, gives the best hope of a cure for NSCLC patients, which comprise 80-85% of lung cancer cases. Their long-term survival rate, however, remains unsatisfactory, and no more than 50% of the cases, who have successfully undergone potentially curative resection, survive for more than 5 years after operation, the remaining cases eventually suffering widespread metastases or local recurrence.